- Home
- SISI vs HOOK Comparison
SISI vs HOOK Comparison
Compare SISI & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- HOOK
- Stock Information
- Founded
- SISI 1997
- HOOK 2011
- Country
- SISI China
- HOOK United States
- Employees
- SISI N/A
- HOOK N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- HOOK Health Care
- Exchange
- SISI Nasdaq
- HOOK Nasdaq
- Market Cap
- SISI 14.9M
- HOOK 9.3M
- IPO Year
- SISI 2016
- HOOK 2019
- Fundamental
- Price
- SISI $0.80
- HOOK $1.47
- Analyst Decision
- SISI
- HOOK Buy
- Analyst Count
- SISI 0
- HOOK 4
- Target Price
- SISI N/A
- HOOK $10.67
- AVG Volume (30 Days)
- SISI 603.5K
- HOOK 134.3K
- Earning Date
- SISI 05-19-2025
- HOOK 05-20-2025
- Dividend Yield
- SISI N/A
- HOOK N/A
- EPS Growth
- SISI N/A
- HOOK N/A
- EPS
- SISI N/A
- HOOK N/A
- Revenue
- SISI $11,072,553.00
- HOOK $43,946,000.00
- Revenue This Year
- SISI N/A
- HOOK N/A
- Revenue Next Year
- SISI N/A
- HOOK N/A
- P/E Ratio
- SISI N/A
- HOOK N/A
- Revenue Growth
- SISI 145.88
- HOOK 118.32
- 52 Week Low
- SISI $0.39
- HOOK $0.72
- 52 Week High
- SISI $117.65
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- SISI 47.99
- HOOK 67.61
- Support Level
- SISI $0.39
- HOOK $1.14
- Resistance Level
- SISI $0.90
- HOOK $1.67
- Average True Range (ATR)
- SISI 0.18
- HOOK 0.16
- MACD
- SISI 0.01
- HOOK 0.10
- Stochastic Oscillator
- SISI 54.30
- HOOK 78.69
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.